What is Surf Bio?
Surf Bio is a preclinical biopharmaceutical company focused on developing advanced therapeutic solutions across a spectrum of critical health areas, including diabetes, oncology, infectious diseases, and gene therapy. The company's foundation is built upon a novel biotechnology platform designed to enhance drug stabilization. This breakthrough technology, originating from the Appel Lab and commercialized by the founders of Bigfoot Biomedical and Mode AGC, aims to revolutionize pharmaceutical delivery and storage. Key commercial advantages include the potential to reduce refrigeration needs, facilitate the transition from intravenous to subcutaneous therapies, and enable innovative pharmaceutical formulations for a wide range of applications.
How much funding has Surf Bio raised?
Surf Bio has raised a total of $16M across 1 funding round:
Angel/Seed
$16M
Angel/Seed (2022): $16M with participation from Breakout Ventures and Perceptive Xontogeny Venture Fund
Key Investors in Surf Bio
Breakout Ventures
Breakout Ventures is a venture capital firm focused on investing in transformative companies that leverage scientific innovation and technology to create new markets. With over a decade of experience, they partner with exceptional founders to scale scientific advancements into category-defining companies. Their portfolio includes firms specializing in areas such as immune-mediated disease diagnosis, sustainable biofabrication, and gene therapy. Breakout Ventures emphasizes early investment with conviction and maintains strong relationships within the industry to help their portfolio companies achieve rapid growth.
Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund is an investment firm that typically backs companies in the life sciences and biotechnology sectors, focusing on early-stage and growth-stage opportunities. Their investment thesis often centers on companies with innovative technologies and strong scientific foundations aimed at addressing unmet medical needs.
What's next for Surf Bio?
With its recent major strategic investment, Surf Bio is poised for significant expansion and advancement of its drug stabilization technology. The substantial capital infusion, part of its {{totalFundingContext}} funding, indicates a strong market belief in the company's innovative approach and its potential to disrupt multiple therapeutic markets. This financing will likely accelerate preclinical development, support regulatory pathway planning, and potentially expand the company's pipeline into new disease areas. The strategic nature of the investment suggests a focus on scaling operations and forging key partnerships to bring its novel therapeutic solutions to market.
See full Surf Bio company page
